William M Grady

List of Publications by Year
in descending order

73 papers	7,460 citations	125106 35 h-index	97045 71 g-index
76 all docs	76 docs citations	76 times ranked	14798 citing authors

#	Article	IF	Citations
1	Validation of genetic classifiers derived from mouse and human tumors to identify molecular subtypes of colorectal cancer. Human Pathology, 2022, 119, 1-14.	1.1	1
2	Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon. Cancer Research, 2022, 82, 1492-1502.	0.4	13
3	Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1473-1482.	1.1	4
4	Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia. Clinical Cancer Research, 2022, 28, 3761-3769.	3.2	2
5	Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. Gastroenterology, 2021, 160, 690-709.	0.6	112
6	Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. Cancers, 2021, 13, 3817.	1.7	15
7	Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness. ELife, 2021, 10, .	2.8	26
8	DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. , 2021, 9, e002671.		37
9	Genomic and functional characterization of a mucosal symbiont involved in early-stage colorectal cancer. Cell Host and Microbe, 2021, 29, 1589-1598.e6.	5.1	44
10	Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. Advances in Cancer Research, 2021, 151, 425-468.	1.9	20
11	Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26.	13.5	125
12	Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk. Clinical Epigenetics, 2020, 12, 5.	1.8	47
13	Epigenetic Aging: More Than Just a Clock When It Comes to Cancer. Cancer Research, 2020, 80, 367-374.	0.4	71
14	Circulating Folate and Folic Acid Concentrations: Associations With Colorectal Cancer Recurrence and Survival. JNCI Cancer Spectrum, 2020, 4, pkaa051.	1.4	9
15	Epigenetic Inactivation of Î±-Internexin Accelerates Microtubule Polymerization in Colorectal Cancer. Cancer Research, 2020, 80, 5203-5215.	0.4	14
16	Chemoprevention of esophageal adenocarcinoma. Gastroenterology Report, 2020, 8, 253-260.	0.6	8
17	Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2486-2494.	1.1	13
18	The Role of CT-Quantified Body Composition on Longitudinal Health-Related Quality of Life in Colorectal Cancer Patients: The Colocare Study. Nutrients, 2020, 12, 1247.	1.7	11

#	Article	IF	Citations
19	Risk factors for cancer-related distress in colorectal cancer survivors: one year post surgery. Journal of Cancer Survivorship, 2020, 14, 305-315.	1.5	17
20	AGA White Paper: Roadmap for the Future of Colorectal Cancer Screening in the United States. Clinical Gastroenterology and Hepatology, 2020, 18, 2667-2678.e2.	2.4	29
21	Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2431-2440.	1.1	23
22	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	3.0	129
23	Subtypes of Barrettâ€™s oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut, 2019, 68, 389-399.	6.1	37
24	Senescenceâ€associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15. Aging Cell, 2019, 18, e13013.	3.0	69
25	Novel Barrettâ€™s esophagus screening assays based on swallowable devices: will they change the game?. Translational Gastroenterology and Hepatology, 2019, 4, 25-25.	1.5	1
26	The ColoCare Study: A Paradigm of Transdisciplinary Science in Colorectal Cancer Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 591-601.	1.1	48
27	Implications of Epigenetic Drift in Colorectal Neoplasia. Cancer Research, 2019, 79, 495-504.	0.4	26
28	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery, 2018, 8, 730-749.	7.7	367
29	Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. British Journal of Cancer, 2018, 118, 1639-1647.	2.9	16
30	Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Developmental Cell, 2018, 45, 738-752.e6.	3.1	27
31	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut, 2018, 67, 1995-2005.	6.1	188
32	BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis. Gut, 2017, 66, 852-862.	6.1	43
33	Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer. British Journal of Cancer, 2017, 117, 1202-1210.	2.9	45
34	Identification of a key role of widespread epigenetic drift in Barrettâ€™s esophagus and esophageal adenocarcinoma. Clinical Epigenetics, 2017, 9, 113.	1.8	19
35	Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1479-1485.	2.3	21
36	WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. Clinical Cancer Research, 2016, 22, 4612-4622.	3.2	9

#	Article	IF	Citations
37	Single cell lineage tracing reveals a role for Tgfî²R2 in intestinal stem cell dynamics and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12192-12197.	3.3	19
38	Global DNA methylation patterns in Barrettâ€™s esophagus, dysplastic Barrettâ€™s, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clinical Epigenetics, 2016, 8, 111.	1.8	26
39	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology, 2016, 151, 440-447.e1.	0.6	36
40	Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. Clinical Colorectal Cancer, 2016, 15, 164-169.	1.0	24
41	Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 727-735.	1.1	10
42	A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrettâ€™s Esophagus. PLoS Computational Biology, 2016, 12, e1004919.	1.5	36
43	Colorectal cancer. Nature Reviews Disease Primers, 2015, 1, 15065.	18.1	1,104
44	Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1890-1897.	1.1	11
45	Molecular markers for colorectal cancer screening. Gut, 2015, 64, 1485-1494.	6.1	100
46	Epigenetic Alterations in Colorectal Cancer: EmergingÂBiomarkers. Gastroenterology, 2015, 149, 1204-1225.e12.	0.6	561
47	Polymerase Slippage Restoration of Frameshifted TGFBR2 in Colorectal Cancer: A Novel Paradigm. Gastroenterology, 2015, 148, 1276-1279.	0.6	6
48	MethyLight droplet digital PCR for detection and absolute quantification of infrequently methylated alleles. Epigenetics, 2015, 10, 803-809.	1.3	63
49	Genetic and Epigenetic Alterations in Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology Clinics of North America, 2015, 44, 473-489.	1.0	50
50	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Research, 2015, 25, 305-315.	2.4	313
51	Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics, 2014, 9, 492-502.	1.3	60
52	Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nature Communications, 2014, 5, 4988.	5.8	219
53	Field cancerization in the colon: a role for aberrant DNA methylation?. Gastroenterology Report, 2014, 2, 16-20.	0.6	47
54	Differences in DNA Methylation Signatures Reveal Multiple Pathways of Progression From Adenoma to Colorectal Cancer. Gastroenterology, 2014, 147, 418-429.e8.	0.6	170

#	Article	IF	Citations
55	Molecular Alterations and Biomarkers in Colorectal Cancer. Toxicologic Pathology, 2014, 42, 124-139.	0.9	80
56	Comparative effectiveness of next generation genomic sequencing for disease diagnosis: Design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemporary Clinical Trials, 2014, 39, 1-8.	0.8	17
57	Epigenetic biomarkers in esophageal cancer. Cancer Letters, 2014, 342, 193-199.	3.2	90
58	Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research. Gastroenterology, 2014, 146, 1586-1590.	0.6	5
59	CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. Gastroenterology, 2014, 147, 637-645.	0.6	118
60	Increased Dietary Vitamin D Suppresses MAPK Signaling, Colitis, and Colon Cancer. Cancer Research, 2014, 74, 4398-4408.	0.4	106
61	GRG Update: DDW 2013. Digestive Diseases and Sciences, 2013, 58, 2127-2128.	1.1	0
62	Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers. Translational Oncology, 2013, 6, 458-IN10.	1.7	40
63	Plasma 25-hydroxyvitamin D3, folate and vitamin B12 biomarkers among international colorectal cancer patients: a pilot study. Journal of Nutritional Science, 2013, 2, e9.	0.7	3
64	NTRK3 Is a Potential Tumor Suppressor Gene Commonly Inactivated by Epigenetic Mechanisms in Colorectal Cancer. PLoS Genetics, 2013, 9, e1003552.	1.5	77
65	Context is everything for dependence receptors in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2697-2698.	3.3	6
66	Epigenetics and colorectal cancer. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 686-700.	8.2	577
67	Colorectal cancer molecular biology moves into clinical practice. Gut, 2011, 60, 116-129.	6.1	280
68	Comparative Analysis of PCR-Based Biomarker Assay Methods for Colorectal Polyp Detection from Fecal DNA. Clinical Chemistry, 2009, 55, 1559-1563.	1.5	52
69	The aberrant methylation of TSP1 suppresses TGFâ€î²1 activation in colorectal cancer. International Journal of Cancer, 2008, 123, 14-21.	2.3	44
70	Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis. Gastroenterology, 2008, 135, 1079-1099.	0.6	786
71	CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes and Cancer, 2006, 45, 781-789.	1.5	96
72	Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clinical Cancer Research, 2005, 11, 1203-9.	3.2	116

#	Article	IF	Citations
73	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17.	9.4	420